Anti-Laminin alpha 5 monoclonal antibody, clone 4B12
| Inventor | Institute |
|---|---|
| Sulev Ingerpuu | University of Tartu |
| Cat. #: | 162128 |
|---|---|
| Application: | IF/ICC |
| Target: | Laminin alpha 5 |
| Reactivity: | Human |
| Clone: | 4B12 |
| Host: | Mouse |
| Class: | Monoclonal |
| Primary citation: | Pook et al. 2014. J Thromb Haemost. 12(4):519-27. PMID: 24450402 |
| Product description: | Anti-Laminin alpha 5 (LMa5) monoclonal antibody, clone 4B12. Antibody against LMa5 used in IHC and ICC. Antibody has previously been conjugated with biotin by Pook et al 2014. |
|---|---|
| Conjugation: | Unconjugated |
| Isotype: | IgG |
| Molecular weight: | 400 kDa |
| Immunogen: | Natural human laminin-511 purified from A549 lung adenocarcinoma cells |
| Target background: | Laminin alpha 5 is one of the subunits of laminin 5, one of the extracellular matrix glycoproteins abundantly present in the basement membranes of blood vessels. Laminin 5 is involved in many biological processes, such as cell adhesion, differentiation, migration, signalling, neurite outgrowth and metastasis. |
|---|
| Shipping conditions: | Dry ice |
|---|
| References: |
Schmal et al. 2016. Stem Cells Int. 4148093, PMID: 26839560 Pook et al. 2014. J Thromb Haemost. 12(4):519-27. PMID: 24450402 |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151023 | Anti-IL12 [1-1D5] |
Key Info
Anti-IL12 [1-1D5]
|
View Tool | |||||||||||||||||||
| 151027 | Anti-HSVICP8 [10A3] |
Key Info
Anti-HSVICP8 [10A3]
|
View Tool | |||||||||||||||||||
| 151033 | Anti-HSVUL42 [13C9] |
Key Info
Anti-HSVUL42 [13C9]
|
View Tool | |||||||||||||||||||
| 151034 | Anti-HSVUL42 [13D11] |
Key Info
Anti-HSVUL42 [13D11]
|
View Tool | |||||||||||||||||||
| 151020 | Anti-CyclinB1 [V143.1] |
Key Info
Anti-CyclinB1 [V143.1]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.